Novo is "pleased" with the 23% weight loss that CagriSema caused, which shows that it offers "clinically meaningful additive weight loss effects" that are superior to what's been seen with drugs that only target GLP-1, Chief Scientific Officer Martin Holst Lange said in a release on Monday
[DOI] [PubMed] [Google Scholar] 15.Sikiric P., Seiwerth S., Rucman R., Turkovic B., Rokotov D.S., Brcic L., Sever M., Klicek R., Radic B., Drmic D., et al
Vascular function and atherosclerosis progression after 1 y of flavonoid intake in statin-treated postmenopausal women with type 2 diabetes: a double-blind randomized controlled trial
Add a small glass of water and you get a strong, concentrated drink
Erosions resolved, 12 months symptom-free after treatment ended
Proc Natl Acad Sci USA 1993